Historical Valuation
Theravance Biopharma Inc (TBPH) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.89 is considered Undervalued compared with the five-year average of -53.11. The fair price of Theravance Biopharma Inc (TBPH) is between 42.59 to 57.78 according to relative valuation methord. Compared to the current price of 19.04 USD , Theravance Biopharma Inc is Undervalued By 55.29%.
Relative Value
Fair Zone
42.59-57.78
Current Price：19.04
55.29%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Theravance Biopharma Inc (TBPH) has a current Price-to-Book (P/B) ratio of 3.95. Compared to its 3-year average P/B ratio of 2.34 , the current P/B ratio is approximately 68.97% higher. Relative to its 5-year average P/B ratio of 0.57, the current P/B ratio is about 589.15% higher. Theravance Biopharma Inc (TBPH) has a Forward Free Cash Flow (FCF) yield of approximately 26.47%. Compared to its 3-year average FCF yield of -5.21%, the current FCF yield is approximately -608.06% lower. Relative to its 5-year average FCF yield of -13.34% , the current FCF yield is about -298.39% lower.
P/B
Median3y
2.34
Median5y
0.57
FCF Yield
Median3y
-5.21
Median5y
-13.34
Competitors Valuation Multiple
AI Analysis for TBPH
The average P/S ratio for TBPH competitors is 68.62, providing a benchmark for relative valuation. Theravance Biopharma Inc Corp (TBPH.O) exhibits a P/S ratio of 8.89, which is -87.05% above the industry average. Given its robust revenue growth of 18.51%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for TBPH
1Y
3Y
5Y
Market capitalization of TBPH increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of TBPH in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is TBPH currently overvalued or undervalued?
Theravance Biopharma Inc (TBPH) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.89 is considered Undervalued compared with the five-year average of -53.11. The fair price of Theravance Biopharma Inc (TBPH) is between 42.59 to 57.78 according to relative valuation methord. Compared to the current price of 19.04 USD , Theravance Biopharma Inc is Undervalued By 55.29% .
What is Theravance Biopharma Inc (TBPH) fair value?
TBPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Theravance Biopharma Inc (TBPH) is between 42.59 to 57.78 according to relative valuation methord.
How does TBPH's valuation metrics compare to the industry average?
The average P/S ratio for TBPH's competitors is 68.62, providing a benchmark for relative valuation. Theravance Biopharma Inc Corp (TBPH) exhibits a P/S ratio of 8.89, which is -87.05% above the industry average. Given its robust revenue growth of 18.51%, this premium appears unsustainable.
What is the current P/B ratio for Theravance Biopharma Inc (TBPH) as of Jan 09 2026?
As of Jan 09 2026, Theravance Biopharma Inc (TBPH) has a P/B ratio of 3.95. This indicates that the market values TBPH at 3.95 times its book value.
What is the current FCF Yield for Theravance Biopharma Inc (TBPH) as of Jan 09 2026?
As of Jan 09 2026, Theravance Biopharma Inc (TBPH) has a FCF Yield of 26.47%. This means that for every dollar of Theravance Biopharma Inc’s market capitalization, the company generates 26.47 cents in free cash flow.
What is the current Forward P/E ratio for Theravance Biopharma Inc (TBPH) as of Jan 09 2026?
As of Jan 09 2026, Theravance Biopharma Inc (TBPH) has a Forward P/E ratio of 25.06. This means the market is willing to pay $25.06 for every dollar of Theravance Biopharma Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Theravance Biopharma Inc (TBPH) as of Jan 09 2026?
As of Jan 09 2026, Theravance Biopharma Inc (TBPH) has a Forward P/S ratio of 8.89. This means the market is valuing TBPH at $8.89 for every dollar of expected revenue over the next 12 months.